

Cluster Headache Market by Drug class (Ergot derivatives, Calcium channel blockers, Triptans and Others), Distribution channel (Hospital pharmacies, Drug stores and retail pharmacies and Others), Type (Episodic and Chronic) and Geography (North America, Europe, Asia Pacific and RoW) – Forecast up to 2027

<https://marketpublishers.com/r/CB1F69B88EF4EN.html>

Date: July 2023

Pages: 222

Price: US\$ 4,500.00 (Single User License)

ID: CB1F69B88EF4EN

Abstracts

The most common types of primary headaches are cluster headaches which are known as trigeminal autonomic cephalgia. These cluster headaches can come every other day, one to eight times a day like other trigeminal autonomic cephalgia's. Approximately, they commonly occur at same time of the day, most often at night. Many patients are periodic, with daily attacks for weeks to months, followed by remission for months to years. As cluster headaches are rare, they can be significantly exhausting, leading to a highly reduction in quality of life. The prevalence and incidence of cluster headaches are rising, which is augmenting the demand for effective treatments which is a key driving factor. Moreover, currently, there are no FDA-approved medications especially for the cluster headaches treatment. This implies that there is a major unmet requirement for effective treatments for this condition, which is augmenting the research and development efforts in this area. On the other hand, the factors limiting the cluster headache market growth are adverse effects of cluster headache drugs. The Cluster Headache Market is anticipated to grow at a rate of 3.9% CAGR by 2027.

Cluster Headache Market by Drug class

Ergot derivatives

Calcium channel blockers

Cluster Headache Market by Drug class (Ergot derivatives, Calcium channel blockers, Triptans and Others), Dist...

Triptans

Others

Cluster Headache Market by Distribution channel

Hospital pharmacies

Drug stores and retail pharmacies

Others

Cluster Headache Market by Type

Episodic

Chronic

Cluster Headache Market by Geography

North America

Europe

Asia Pacific

Rest of the World

The cluster headache market by drug class is divided into Ergot derivatives, Calcium channel blockers, Triptans and Others. The triptans segment holds the maximum share in the market growth. The maximum share of the segment is owing to the first line treatment for cluster headache. Triptans are a class, or group, of medicines which can stop migraine episodes. These drugs work to decrease symptoms by building enlarged blood arteries in the brain brought on by migraine attacks. Also, they are present in various dose formulations.

On the basis of distribution channel, the cluster headache market is categorized into Hospital pharmacies, Drug stores and retail pharmacies and Others. The drug stores and retail pharmacies segment held the maximum share in the market growth. This is due to the increase in consumer preference for retail pharmacies, which provide advice on drugs and their use throughout treatment periods and they also provide affordable prices.

As per the type the cluster headache market is bifurcated into Episodic and Chronic. The episodic segment accounted for the major share in the cluster headache market. The major share is owing to the surge in number of people suffering from episodic

attack and increase in regulatory approval of drugs indicated for episodic cluster headache.

The regional market is divided into North America, Europe, Asia Pacific and rest of the world. North America region has occupied the major share in the cluster headache market growth due to the factors such as surge in prevalence of cluster headache cases, incidence of advanced healthcare infrastructure and rise in number of key players providing new therapeutics.

Several organizations coupled with governments across the world are counseling people about the headache disorders. E-commerce (electronic commerce) has become a significant tool for small and large businesses globally, owing to increase in preference of consumers for online shopping over conventional purchasing methods. Several animations through health apps to educate people about headache disorders and usage of medications have lead towards the growth of global cluster headache market.

Key players operating in the cluster headache market include Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., FRESENIUS SE & Co. KGaA, GlaxoSmithKline plc, Pfizer Inc., Arrotex Australia Group, Grunenthal, and Novartis AG.

As a result, there is a major unmet requirement for effective treatments for cluster headaches. Henceforth, there is a rising focus on the development of new treatments, such as new pharmacological agents and neuromodulation devices which is projected to augment innovation in the market.

Complete information on factors is provided which will propel cluster headache market growth in the forecast period.

This report gives the exact estimation of the market size and its contribution to the parent market along with the precise estimation on upcoming trends and shifts in consumer behavior.

This research provides growth analysis of the cluster headache market among regions such as North America, Europe, Asia Pacific and rest of the world.

This report further provides comprehensive details of factors which will challenge the growth of cluster headache market players.

Contents

1. EXECUTIVE SUMMARY

2. INDUSTRY OUTLOOK

3. INDUSTRY OVERVIEW

4. INDUSTRY TRENDS

5. MARKET SNAPSHOT

6. MARKET DEFINITION

7. MARKET OUTLOOK

a. Porter Five Forces

8. RELATED MARKETS

9. MARKET CHARACTERISTICS

10. MARKET OVERVIEW

11. MARKET SEGMENTATION

12. MARKET DYNAMICS

a. Drivers

b. Restraints

c. Opportunities

13. DRO - IMPACT ANALYSIS

14. DRUG CLASS: MARKET SIZE & ANALYSIS

15. OVERVIEW

16. ERGOT DERIVATIVES

17. CALCIUM CHANNEL BLOCKERS

18. TRIPTANS

19. OTHERS

20. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS

21. OVERVIEW

22. HOSPITAL PHARMACIES

23. DRUG STORES AND RETAIL PHARMACIES

24. OTHERS

25. TYPE: MARKET SIZE & ANALYSIS

26. OVERVIEW

27. EPISODIC

28. CHRONIC

29. GEOGRAPHY: MARKET SIZE & ANALYSIS

30. OVERVIEW

31. NORTH AMERICA

32. EUROPE

33. ASIA PACIFIC

34. REST OF THE WORLD

35. COMPETITIVE LANDSCAPE

36. COMPETITOR COMPARISON ANALYSIS

37. MARKET DEVELOPMENTS

- a. Mergers and Acquisitions, Legal, Awards, Partnerships
- b. Product Launches and execution

38. VENDOR PROFILES

39. DR. REDDY'S LABORATORIES LTD.

- a. Overview
- b. Financial Overview
- c. Product Offerings
- d. Developments
- e. Business Strategy

40. ELI LILLY AND COMPANY

- a. Overview
- b. Financial Overview
- c. Product Offerings
- d. Developments
- e. Business Strategy

41. SUN PHARMACEUTICAL INDUSTRIES LTD.

- a. Overview
- b. Financial Overview
- c. Product Offerings
- d. Developments
- e. Business Strategy

42. TEVA PHARMACEUTICAL INDUSTRIES LTD.

- a. Overview
- b. Financial Overview
- c. Product Offerings

- d. Developments
- e. Business Strategy

43. FRESENIUS SE & CO. KGAA

- a. Overview
- b. Financial Overview
- c. Product Offerings
- d. Developments
- e. Business Strategy

44. GLAXOSMITHKLINE PLC

- a. Overview
- b. Financial Overview
- c. Product Offerings
- d. Developments
- e. Business Strategy

45. PFIZER INC.

- a. Overview
- b. Financial Overview
- c. Product Offerings
- d. Developments
- e. Business Strategy

46. ARROTEX AUSTRALIA GROUP

- a. Overview
- b. Financial Overview
- c. Product Offerings
- d. Developments
- e. Business Strategy

47. GRUNENTHAL

- a. Overview
- b. Financial Overview

- c. Product Offerings
- d. Developments
- e. Business Strategy

48. NOVARTIS AG

- a. Overview
- b. Financial Overview
- c. Product Offerings
- d. Developments
- e. Business Strategy

49. ANALYST OPINION

50. ANNEXURE

51. REPORT SCOPE

52. MARKET DEFINITIONS

53. RESEARCH METHODOLOGY

- a. Data Collation and In-house Estimation
- b. Market Triangulation
- c. Forecasting

54. REPORT ASSUMPTIONS

55. DECLARATIONS

56. STAKEHOLDERS

57. ABBREVIATIONS

List Of Tables

LIST OF TABLES

TABLE 1. GLOBAL CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 2. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR ERGOT DERIVATIVES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 3. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR TRIPTANS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 4. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 5. GLOBAL CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 6. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 7. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 8. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 9. GLOBAL CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 10. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR EPISODIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 11. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR CHRONIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 12. NORTH AMERICA CLUSTER HEADACHE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 13. NORTH AMERICA CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 14. NORTH AMERICA CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 15. NORTH AMERICA CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 16. U.S CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 17. U.S CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 18. U.S CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD

BILLION)

TABLE 19. CANADA CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 20. CANADA CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 21. CANADA CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 22. EUROPE CLUSTER HEADACHE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 23. EUROPE CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 24. EUROPE CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 25. EUROPE CLUSTER HEADACHE MARKET VALUE, TYPE, 2021-2027 (USD BILLION)

TABLE 26. GERMANY CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 27. GERMANY CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 28. GERMANY CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 29. U.K CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 30. U.K CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 31. U.K CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 32. FRANCE CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 33. FRANCE CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 34. FRANCE CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 35. ITALY CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 36. ITALY CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 37. ITALY CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 38. SPAIN CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 39. SPAIN CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 40. SPAIN CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 41. ROE CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 42. ROE CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 43. ROE CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 44. ASIA PACIFIC CLUSTER HEADACHE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 45. ASIA PACIFIC CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 46. ASIA PACIFIC CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 47. ASIA PACIFIC CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 48. CHINA CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 49. CHINA CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 50. CHINA CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 51. INDIA CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 52. INDIA CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 53. INDIA CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 54. JAPAN CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 55. JAPAN CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 56. JAPAN CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 57. REST OF APAC CLUSTER HEADACHE MARKET VALUE, BY DRUG

CLASS, 2021-2027 (USD BILLION)

TABLE 58. REST OF APAC CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 59. REST OF APAC CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 60. REST OF WORLD CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)

TABLE 61. REST OF WORLD CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 62. REST OF WORLD CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 63. DR. REDDY'S LABORATORIES LTD.: FINANCIALS

TABLE 64. DR. REDDY'S LABORATORIES LTD.: PRODUCTS & TYPES

TABLE 65. DR. REDDY'S LABORATORIES LTD.: RECENT DEVELOPMENTS

TABLE 66. ELI LILLY AND COMPANY: FINANCIALS

TABLE 67. ELI LILLY AND COMPANY: PRODUCTS & TYPES

TABLE 68. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS

TABLE 69. SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIALS

TABLE 70. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS & TYPES

TABLE 71. SUN PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS

TABLE 72. TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIALS

TABLE 73. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS & TYPES

TABLE 74. TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS

TABLE 75. FRESENIUS SE & CO. KGAA: FINANCIALS

TABLE 76. FRESENIUS SE & CO. KGAA: PRODUCTS & TYPES

TABLE 77. FRESENIUS SE & CO. KGAA: RECENT DEVELOPMENTS

TABLE 78. GLAXOSMITHKLINE PLC: FINANCIALS

TABLE 79. GLAXOSMITHKLINE PLC: PRODUCTS & TYPES

TABLE 80. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS

TABLE 81. PFIZER INC.: FINANCIALS

TABLE 82. PFIZER INC.: PRODUCTS & TYPES

TABLE 83. PFIZER INC.: RECENT DEVELOPMENTS

TABLE 84. ARROTEX AUSTRALIA GROUP: FINANCIALS

TABLE 85. ARROTEX AUSTRALIA GROUP: PRODUCTS & TYPES

TABLE 86. ARROTEX AUSTRALIA GROUP: RECENT DEVELOPMENTS

TABLE 87. GRUNENTHAL: FINANCIALS

TABLE 88. GRUNENTHAL: PRODUCTS & TYPES

TABLE 89. GRUNENTHAL: RECENT DEVELOPMENTS

TABLE 90. NOVARTIS AG: FINANCIALS

TABLE 91. NOVARTIS AG: PRODUCTS & TYPES

TABLE 92. NOVARTIS AG: RECENT DEVELOPMENTS

I would like to order

Product name: Cluster Headache Market by Drug class (Ergot derivatives, Calcium channel blockers, Triptans and Others), Distribution channel (Hospital pharmacies, Drug stores and retail pharmacies and Others), Type (Episodic and Chronic) and Geography (North America, Europe, Asia Pacific and RoW) – Forecast up to 2027

Product link: <https://marketpublishers.com/r/CB1F69B88EF4EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CB1F69B88EF4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970